Skip to main content
Smart Investors Daily
Viatris Inc. logo

NASDAQ · VTRS

Viatris Inc.

Healthcare · Drug Manufacturers - Specialty & Generic

$20.74

Down-$0.08 (-0.38%)

Updated Nov 17, 2026, 11:02 AM

SID Score

7.6/10

Composite research score

Smart Money

62/100

Neutral

Market cap
13.35B
P/E ratio
-3.66
Dividend yield
2.31%
52-week range
$12.55 – $21.20
Volume
15.68M
Avg. volume
9.37M

Price performance · VTRS

VTRS price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 16, 2026

VTRS closed at $20.74 after 21 trading sessions, up 13.58% for the selected period.

Last close
$20.74
Period change
+13.58%
Period low
$18.00
Period high
$21.06
Daily close
View OHLC price history
VTRS OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 16, 2026$20.89$20.99$20.61$20.7415.68M
Nov 13, 2026$20.77$20.865$20.385$20.826.51M
Nov 12, 2026$21.05$21.20$20.65$20.678.79M
Nov 11, 2026$20.755$21.10$20.595$21.0614.45M
Nov 10, 2026$20.41$20.86$20.262$20.8511.18M
Nov 9, 2026$20.11$20.53$19.90$20.4912.64M
Nov 6, 2026$18.79$19.94$18.79$19.9114.53M
Nov 5, 2026$19.43$19.96$18.785$18.9711.92M
Nov 4, 2026$19.325$19.325$18.71$19.228.45M
Nov 3, 2026$18.70$18.94$18.64$18.927.55M
Nov 2, 2026$19.06$19.12$18.65$18.677.25M
Oct 30, 2026$19.29$19.505$19.00$19.0358.79M
Oct 29, 2026$18.97$19.23$18.93$19.2010.49M
Oct 28, 2026$18.535$18.93$18.46$18.777.85M
Oct 27, 2026$18.19$18.83$18.17$18.726.07M
Oct 26, 2026$18.20$18.395$18.11$18.296.06M
Oct 23, 2026$18.33$18.3805$17.86$18.007.22M
Oct 22, 2026$18.45$18.66$18.345$18.485.44M
Oct 21, 2026$18.64$18.695$18.43$18.4510.19M
Oct 20, 2026$18.34$18.685$18.285$18.6514.27M
Oct 19, 2026$18.625$18.7502$18.175$18.2611.53M

Latest VTRS news

The latest Smart Investors Daily articles mentioning VTRS.

VTRS research

Overview

Company profile and research snapshot.

Company profile

Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$15.00
Implied upside
—
Analysts
17
VTRS recent ratings
DateFirmRatingTarget
Nov 6, 2026JP MorganNeutral—
Oct 26, 2026Piper SandlerNeutral—
Oct 21, 2026JP MorganNeutral—
Oct 5, 2026UBSBuy—
Sep 23, 2026OppenheimerOutperform—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Nov 10, 2026

VTRS Q3 2026 deep dive: new product launches and Pacira acquisition shape outlook

Medication company Viatris (NASDAQ:VTRS) fell short of the market’s revenue expectations in Q3 2026, with sales flat year on year at $3.75 billion. On the other hand, the company’s outlook for the full year was close to analysts’ estimates with revenue guided to $14.8 billion at the midpoint. Its non-GAAP profit of $0.71 per share was 11.3% above analysts’ consensus estimates.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.